Cabaletta Bio (CABA) director Catherine Bollard purchases 4,405 shares

Rhea-AI Filing Summary

Cabaletta Bio, Inc. director Catherine Bollard reported a purchase of 4,405 shares of the company’s common stock. The transaction took place on 01/21/2026 at a price of $2.2661 per share, according to a Form 4 insider trading report.

Following this open-market purchase, Bollard’s reported beneficial ownership increased to 5,405 shares, held directly. The filing indicates the transaction code "P," which denotes a purchase of non-derivative securities.

Insider Trade Summary

Net Buyer: 4,405 shares ($9,982)

Net Buy 1 txn

Insider Bollard Catherine

Role Director

Bought 4,405 shs ($10K)

Type	Security	Shares	Price	Value
Purchase	Common Stock	4,405	$2.2661	$10K

Holdings After Transaction: Common Stock — 5,405 shares (Direct)

Footnotes (1)

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Bollard Catherine

(Last) (First) (Middle)

C/O CABALETTA BIO, INC.

2929 ARCH STREET, SUITE 600

(Street)

PHILADELPHIA PA 19104

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Cabaletta Bio, Inc. [ CABA ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
01/21/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/21/2026		P		4,405	A	$2.2661	5,405	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

	By: /s/ Michael Gerard, as Attorney-in-Fact	01/21/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Cabaletta Bio (CABA) report for Catherine Bollard?

The company reported that director Catherine Bollard purchased 4,405 shares of Cabaletta Bio common stock on 01/21/2026.

At what price were the Cabaletta Bio (CABA) shares bought in this Form 4?

The reported purchase price was $2.2661 per share for the 4,405 Cabaletta Bio common shares.

How many Cabaletta Bio (CABA) shares does Catherine Bollard own after the reported transaction?

After the transaction, Catherine Bollard is reported to beneficially own 5,405 shares of Cabaletta Bio common stock.

Is the Cabaletta Bio (CABA) insider transaction direct or indirect ownership?

The Form 4 indicates the ownership form as Direct (D), meaning the 5,405 shares are held directly by Catherine Bollard.

What type of security was involved in this Cabaletta Bio (CABA) Form 4 filing?

The transaction involved Common Stock of Cabaletta Bio, reported as a non-derivative security in Table I of the Form 4.

What does transaction code "P" mean in the Cabaletta Bio (CABA) Form 4?

Transaction code "P" in the Form 4 indicates an open-market or private purchase of non-derivative securities.